Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Sees Large Increase in Short Interest

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totalling 44,400 shares, an increase of 114.5% from the June 30th total of 20,700 shares. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is presently 0.0 days.

Scinai Immunotherapeutics Trading Up 15.6 %

Shares of NASDAQ:SCNI traded up $0.59 during midday trading on Friday, hitting $4.36. The stock had a trading volume of 193,624 shares, compared to its average volume of 1,592,664. The company has a market capitalization of $2.01 million, a PE ratio of -0.02 and a beta of 2.50. The stock has a 50 day moving average price of $3.70 and a two-hundred day moving average price of $4.47. Scinai Immunotherapeutics has a 1 year low of $2.23 and a 1 year high of $14.20.

Scinai Immunotherapeutics (NASDAQ:SCNI) last issued its earnings results on Tuesday, July 2nd. The company reported ($4.00) earnings per share for the quarter.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.